TY - JOUR
T1 - A novel approach to the development of positive inotropic agents for chronic heart failure
AU - Packer, M.
PY - 1995
Y1 - 1995
N2 - Although positive inotropic agents exert favorable hemodynamic effects, long-term therapy with these drugs has not produced clinical benefits and has increased the mortality of patients with chronic congestive heart failure (CHF). This experience has led many physicians to suggest that positive inotropic therapy be abandoned as a therapeutic approach for this condition. However, positive inotropic drugs can produce clinical benefits in many patients but, ironically, this improvement may be principally seen at doses that produce negligible effects on cardiac contractility. This apparent discrepancy may be explained by the fact that many positive inotropic agents exert actions on the circulation in addition to stimulating the heart, and these ancillary properties may be particularly important with the use of low doses of these drugs. If the noninotropic actions of low doses are responsible for the therapeutic benefits of these drugs, the positive inotropic effects seen at high doses may be primarily responsible for their adverse (rather than their favorable) effects. Therefore, hemodynamic activity should not be viewed as a prerequisite for the selection of the dose of a drug for CHF. The ideal dose of a positive inotropic agent may be one that exerts no positive inotropic effect at all.
AB - Although positive inotropic agents exert favorable hemodynamic effects, long-term therapy with these drugs has not produced clinical benefits and has increased the mortality of patients with chronic congestive heart failure (CHF). This experience has led many physicians to suggest that positive inotropic therapy be abandoned as a therapeutic approach for this condition. However, positive inotropic drugs can produce clinical benefits in many patients but, ironically, this improvement may be principally seen at doses that produce negligible effects on cardiac contractility. This apparent discrepancy may be explained by the fact that many positive inotropic agents exert actions on the circulation in addition to stimulating the heart, and these ancillary properties may be particularly important with the use of low doses of these drugs. If the noninotropic actions of low doses are responsible for the therapeutic benefits of these drugs, the positive inotropic effects seen at high doses may be primarily responsible for their adverse (rather than their favorable) effects. Therefore, hemodynamic activity should not be viewed as a prerequisite for the selection of the dose of a drug for CHF. The ideal dose of a positive inotropic agent may be one that exerts no positive inotropic effect at all.
KW - Glycosides
KW - Inotropic agents
KW - Phosphodiesterase inhibitors
KW - β-Adrenergic agonists
UR - http://www.scopus.com/inward/record.url?scp=0029562898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029562898&partnerID=8YFLogxK
U2 - 10.1097/00005344-199500001-00007
DO - 10.1097/00005344-199500001-00007
M3 - Article
C2 - 8907131
AN - SCOPUS:0029562898
SN - 0160-2446
VL - 26
SP - S52-S56
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
ER -